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Clinical Trials
Thrombolytic-Facilitated PCI Superior to Thrombolysis Alone for
High-Risk MI
While emergent percutaneous coronary intervention (PCI) appears to be supe-rior to thrombolysis when the appropriate facilities are readily available, previ-
ous studies have shown that the option of giving thrombolytics and then proceeding to
urgent percutaneous transluminal coronary angioplasty is associated with higher rates
of bleeding and no significant benefit. However, most of these studies were done with
non–fibrin-specific thrombolytic agents and balloon angioplasty without stent place-
ment. Le May and colleagues randomized subjects with high risk acute myocardial
infarction to either tenecteplase or tenecteplase-facilitated PCI with balloon inflation
3 h after randomization. Fifty percent fewer PCI patients reached the composite end
point of death, reinfarction, recurrent unstable ischemia or stroke at six months.
Importantly, there was no excess bleedingwith early PCI. Larger studies will be needed
to define the role of thrombolytic facilitated PCI, but the use of fibrin specific agents
and lower doses of heparin appears to have reduced the excess rates of bleeding
associated with this strategy. See page 417. See figure.
Interventional Cardiology
Improved Outcomes With Use of FFR to Characterize Stenoses
Using fractional flow reserve (FFR) for clinical decision making remains contro-versial.This retrospective study examined the clinical outcomes in a large series of
patients with multi-vessel coronary disease in whom intervention was deferred if FFR
was0.75. Lesions with a FFR0.75 were only half as likely to require revascular-
ization over the next three years as the lesions that had FFR0.75 andwere intervened
upon. This study suggests that FFR is a valuable tool to risk-stratify coronary lesions
and that intervention on lesions with an FFR 0.75 should be avoided. See page
438.
Atherosclerosis
Young Subjects With Metabolic Syndrome Have Detectable Atherosclerosis
The metabolic syndrome is characterized by insulin resistance and high bloodpressure, as well as multiple metabolic abnormalities such as abdominal obesity,
hypertriglyceridemia and low high-density lipoprotein. Tzou and colleagues sought to
determine if this syndrome could predict atherosclerotic burden in young adults using
data collected in the Bogalusa Heart Study. They correlated the carotid intima media
thickness (IMT) with the components of the metabolic syndrome in over 500 young
adults age 20 to 38 years. Both the National Cholesterol Education Program and the
WorldHealthOrganizationdefinitions of themetabolic syndromepredicted increased
IMT. These findings document that atherosclerosis begins early and suggest that
increased screening efforts and aggressive risk factor modification are indicated even in
young subjects. See page 457.
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Hypertrophic and
Dilated Cardiomyopathy
Surgical Myectomy Improves Mortality in Hypertrophic Cardiomyopathy
Surgical myectomy has been used to relieve refractory symptoms in subjects withhypertrophic cardiomyopathy (HCM) for almost 40 years. It has clearly been
shown to improve symptoms and quality of life, but there has been a lingering question
about the effect onmortality given that the underlying process ofHCMis not reversed.
Ommen and colleagues compared total and HCM-related mortality in three sub-
groups of HCM patients: surgical myectomy, left ventricular outflow obstruction
without operation, and nonobstructive HCM. Surgical mortality at this experienced
center was less than 1%. Survival after myectomy was similar to the general U.S.
population and improved compared to subjects with obstructionwho did not undergo
myectomy. This study suggests that myectomy can not only improve symptoms but
also mortality for subjects with obstructive HCM. See page 470. See figure.
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Heart Failure
High Normal Digoxin Levels Associated with Increased Mortality in Women
This study by Adams and colleagues examines the relationship between gender,serumdigoxin levels, andoutcomes in subjectswith systolic dysfunction. Subjects
with serum concentrations between 0.5 and 0.9 ng/ml, had reduced morbidity and
mortality compared to either placebo treated subjects or subjects with concentrations
above 1.2 ng/ml but 2.0. Levels above 1.2 ng/ml were associated with excess
mortality, mostly due to an increased incidence of sudden cardiac death. This finding
suggests that therapeutic range for digoxin should be revised to 0.5 to 1.0 ng/ml for
both men and women with systolic dysfunction. See page 497. See figure.
Hypertension
24-h Blood Pressure Monitoring Improves Predictive Power
Apatient’s blood pressure (BP) in the clinic may not accurately reflect a person’saverage BP. White-coat hypertension (WCHT) is commonly recognized.
Masked hypertension (MHT) refers to the opposite situation inwhich a person’s BP in
the doctor’s office is lower than it is throughout the rest of the day; this may reflect
incomplete coverage of antihypertensive medications, but other etiologies have also
been postulated. Ohkubo and colleagues compared routinely collected BP measure-
ments with 24-h ambulatorymeasurements and then tracked cardiovascular outcomes
in a large cohort of Japanese subjects. Subjects with normal BP and WCHT had
outcomes that were similar and lower than both subjects with sustained hypertension
and MHT. These findings suggest that ambulatory BP measurements are better
predictors of cardiovascular risk than traditional office-based measurements and as
many as one in five subjects may be inappropriately classified based on single measure-
ments. See page 508.
